Biotherapeutics

Multidisciplinary in nature, this programme will appeal to a wide range of candidates from across sectors who work with and/or are planning to work with biomedical therapeutics, including but not limited to life scientists, professionals from the Biopharma and BioPharmaceutical, Biotechnology, Diagnostics and/or Healthcare industries, and medical practitioners (including GPs, clinicians-in-training, and specialist nurses). Graduates will be well placed to provide practice, professional leadership, innovation and scholarship expertise to a vast array of organisations to make a difference in the development and application of biotherapeutics.

Programme structure:



Introduction to Cell Biology and Biotechnology



Recombinant DNA Technology



Immuno- and Onco-Therapeutics



Introduction to Bioprocess Engineering



Biotherapeutic Pipeline



Regulatory Affairs Sc. for Biotech Products



Bioseparations



Neuro & Cardiovascular Therapeutics



Case Studies in Biotherapeutic Development



Professional Skills for Scientists



Practical on Laboratory Techniques



12-week research or design project in DCU or in a course-relevant place of work on a novel research topic related to biomedical science in the module ‘Research Design and Methodology Project’



12-week MasterClass in Biotherapeutics, a bespoke set of experiments relating to the design, purification and validity testing of a monoclonal antibody therapeutic in addition to writing a grant proposal.

To qualify for the MSc in Biotherapeutics programme students will be expected to have a Second Class Honours degree (H2.1) or equivalent in a life science, pharmaceutical or chemistry discipline. Medical graduates must have a MB, BCh, BAO or equivalent from a recognised medical school.



Applicants with equivalent qualifications in related areas of science and technology, or with proven and relevant industrial experience from the Healthcare/Medical/Therapeutics industry may be considered for places following interview and assessment by the programme management team, in line with standard DCU policies.



International candidates who are non-native speakers of English must satisfy the University of their competency in the English language.

Application Deadlines



Applications will be accepted on a rolling basis until the programme is full or until:

Closing date for non EU applicants is 1st July 2024

Closing date for EU applicants is 31st July 2024



Note applicants who require a study visa for the purposes of studying at DCU are advised to apply as early as possible. All entry requirements should be met before the commencement of the programme.



All Applicants must apply through DCU's Student Application Portal which is available at the link below.



Provide Academic Transcripts for each and every year of study with English translation if applicable.

If applicable, provide evidence of competence in the English language as per DCU entry requirements. Please see link http://www.dcu.ie/registry/english.shtml.

Please note if you are a non EU student and require a study visa, you are not eligible to apply for part-time programmes as study visas are only granted for full-time programmes.



Queries

Queries from EU applicants should be directed to postgraduateadmissions@dcu.ie

Queries from non EU applicants should be directed to internationaladmissions@dcu.ie

1 year full-time or 2 years part-time.

The programme commences in September 2024.

Graduates of this programme will be well placed to provide practice, professional leadership, innovation and scholarship expertise to a vast array of organisations to make a difference in the development and application of biotherapeutics; such as in academia, health care, and industry settings, and many more. The programme is designed to enhance postgraduate students’ employability and promotional aspects through the improvement of skills and knowledge of the pathophysiology of disease and the development of next generation of biologics therapies. Lastly, graduates of this programme would be ideal candidates for the structured PhD research programme (BioTranslate) within the School.